Abstract:Metabolic illnesses, including obesity and type 2 diabetes, have become worldwide epidemics that have an effect on public health. Clinical investigations and further exploration of these mechanisms could lead to innovative, effective, and personalized treatment strategies for individuals. It is important to screen biomarkers in previous studies to discover what is missing. Glucagon-like peptide-1′s role in insulin secretion and glucose control highlights its diagnostic and therapeutic potential. Glucose-dependent insulinotropic peptide's influence on postprandial satiety and weight management signifies its importance in understanding metabolic processes. Monocyte chemoattractant protein-1′s involvement in inflammation and insulin resistance underlines its value as a diagnostic marker. Insulin-like growth factor-binding protein-7's association with insulin sensitivity and kidney function presents it as a potential target for these diseases' management. In validating these biomarkers, it will be easier to reflect pathophysiological processes, and clinicians will be able to better assess disease severity, monitor disease progression, and tailor treatment strategies. The purpose of the study was to elucidate the significance of identifying novel biomarkers for type 2 diabetes mellitus and obesity, which can revolutionize early detection, risk assessment, and personalized treatment strategies. Standard literature searches of PubMed (MEDLINE), EMBASE, and Cochrane Library were conducted in the year 2023 to identify both original RCTs and recent systematic reviews that have explored the importance of identifying novel biomarkers for T2D and obesity. This search produced 1964 results, and then was reduced to randomized controlled trial and systematic reviews, producing 145 results and 44 results, respectively. Researchers have discovered potential associations between type 2 diabetes mellitus and obesity and the biomarkers glucagon-like peptide-1, glucose-dependent insulinotropic peptide, monocyte chemoattractant protein-1, and insulin-like growth factor-binding protein-7. Understanding the role of those biomarkers in disease pathogenesis offers hope for improving diagnostics, personalized treatment, and prevention strategies.

Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin

Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes

Novel mechanisms involved in leptin sensitization in obesity

The incretin/glucagon system as a target for pharmacotherapy of obesity

New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists

Novel targets for potential therapeutic use in Diabetes mellitus

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective

Novel secreted regulators of glucose and lipid metabolism in the development of metabolic diseases

The cellular and molecular bases of leptin and ghrelin resistance in obesity

Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy

Is the β3-Adrenoceptor a Valid Target for the Treatment of Obesity and/or Type 2 Diabetes?

Pharmacological Advances in Incretin-based Polyagonism – What we know and what we don'tt

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Leptin revisited: its mechanism of action and potential for treating diabetes

The Role of GLP-1, GIP, MCP-1 and IGFBP-7 Biomarkers in the Development of Metabolic Disorders: A Review and Predictive Analysis in the Context of Diabetes and Obesity

From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity

Targeting the incretin system in obesity and type 2 diabetes mellitus

Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes

Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond